-
Mashup Score: 0
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 3Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs - 1 year(s) ago
AbstractAims. In clinical practice, many patients do not reach the recommended treatment targets for LDL-cholesterol levels. We aimed to examine treatment patte
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @ehjopen: Large proportion of patients with #dyslipidaemia treatment gaps: read the whole story on #EHJOpen: https://t.co/mvXOoX8E1d #O…
-
-
Mashup Score: 0
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Categories: Endocrinology, Latest HeadlinesTweet-
In the February Issue: Risks and burdens of incident #dyslipidaemia in long #COVID: a cohort study https://t.co/cFUB2qgsxc #LongCovid #COVID19 #FREE to read
-
-
Mashup Score: 0The Lancet Diabetes & Endocrinology, February 2023, Volume 11, Issue 2, Pages 63-138, e2 - 1 year(s) ago
Explore the current issue of The Lancet Diabetes & Endocrinology, a monthly journal focussed on diabetes, endocrinology, and metabolism
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
The February Issue of @TheLancetEndo is now online, featuring #T1D in #pregnancy, #insulin, #rtCGM, #PCSK9 inhibitor, #cholesterol, #dyslipidaemia, #LongCovid, #glucagon #centenary, #diabetes #registries, #vitaminD, #teplizumab, #LivedExperiences & more https://t.co/ft8CFDfqG7 https://t.co/sIPuGMaDNs
-
-
Mashup Score: 3Blood lipids after COVID-19 infection - 1 year(s) ago
Atherosclerotic cardiovascular disease incidence is increased both during acute COVID-19 infection and for an indefinite period afterwards.1,2 For this reason it has been recommended that lipid-lowering medication is generally continued throughout the period of active infection and subsequently.2 In this issue of The Lancet Diabetes & Endocrinology, Evan Xu and colleagues3 provide evidence that…
Categories: Cardiologists, Latest HeadlinesTweet-
RT @TheLancetEndo: Paul Durrington comments on: Blood #lipids after #COVID-19 infection https://t.co/ZhJi5QHcyQ #dyslipidaemia #COVID19 #L…
-
-
Mashup Score: 3
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Categories: Endocrinology, Latest HeadlinesTweet-
Risks and burdens of incident #dyslipidaemia in long #COVID: a cohort study https://t.co/cFUB2qfUHE #COVID19 #LongCovid #FREE to read
-
-
Mashup Score: 1Blood lipids after COVID-19 infection - 1 year(s) ago
Atherosclerotic cardiovascular disease incidence is increased both during acute COVID-19 infection and for an indefinite period afterwards.1,2 For this reason it has been recommended that lipid-lowering medication is generally continued throughout the period of active infection and subsequently.2 In this issue of The Lancet Diabetes & Endocrinology, Evan Xu and colleagues3 provide evidence that…
Categories: Endocrinology, Latest HeadlinesTweet-
Paul Durrington comments on: Blood #lipids after #COVID-19 infection https://t.co/ZhJi5QHcyQ #dyslipidaemia #COVID19 #LongCovid #FREE to read
-
-
Mashup Score: 6
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Categories: Endocrinology, Latest HeadlinesTweet-
Risks and burdens of incident #dyslipidaemia in long #COVID: a cohort study https://t.co/cFUB2qfUHE #COVID19 #LongCovid #FREE to read
-
-
Mashup Score: 3Blood lipids after COVID-19 infection - 1 year(s) ago
Atherosclerotic cardiovascular disease incidence is increased both during acute COVID-19 infection and for an indefinite period afterwards.1,2 For this reason it has been recommended that lipid-lowering medication is generally continued throughout the period of active infection and subsequently.2 In this issue of The Lancet Diabetes & Endocrinology, Evan Xu and colleagues3 provide evidence that…
Categories: Endocrinology, Latest HeadlinesTweet-
Linked Comment—Blood #lipids after #COVID-19 infection https://t.co/ZhJi5QHcyQ #dyslipidaemia #COVID19 #LongCovid #FREE to read
-
-
Mashup Score: 2
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Categories: Endocrinology, Latest HeadlinesTweet-
Online—Risks and burdens of incident #dyslipidaemia in long #COVID: a cohort study https://t.co/cFUB2qgsxc #LongCovid #COVID19 #FREE to read
-
RESEARCH: Risks and burdens of incident dyslipidaemia in long #COVID: a cohort study Read the full article where Evan Xu et al aim to identify the 1-year risks and burdens of incident #dyslipidaemia in the post-acute phase of COVID-19. https://t.co/cFUB2qgsxc